Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Inventiva S.A.NASDAQ: IVA

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income grows 30.9% year over year

Q4 FY2025 net income of €176.94M (cash outflow) rose 30.9% year over year. Over 3 fiscal years it compounded at +84.4% a year.

Context

  • Net income amounted to 7587.8% of revenue in FY2025, up 5585.1 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -€135.71M (-60.1%) for the fiscal year ending Dec 2026, a slowdown from the +84.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-€176.94M— QoQ
Last fiscal yearDec 2025
-€340.16M+84.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.9%——
1 year+84.7%-60.1%-144.8 pp
3-year CAGR+84.4%-45.0%-129.4 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(340.16M) EUR
Year-over-year change
-84.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +84.7% is the 2nd highest of 10, against a peer median of -17.6%.
  • Net income amounts to 7587.8% of revenue for IVA, versus a peer median of 1189.1%.
IVA Competitors
Net Income for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€340.16M EUR+84.7%+84.4%7587.8%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$151.77M USD+296.2%—8550.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$133.22M USD-9.9%+14.2%1189.1%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M USD-216.1%+23.4%143627.1%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M USD-21.5%-9.9%36891.1%
IVVDInvivyd, Inc.LTM Mar 2026$77.6M USD-45.6%-39.9%138.9%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M USD-35.7%-12.4%89.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$57.09M USD-16.9%+0.6%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$54.64M USD-17.6%+16.2%167.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$42.72M USD+84.6%+27.3%—
Peer median (excluding IVA) —-17.6%+7.4%1189.1%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.